Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 421

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

Open access
Goodall, Jane, Mateo, Joaquin, Yuan, Wei, Mossop, Helen, Porta, Nuria, Miranda, Susana, Perez-Lopez, Raquel, Dolling, David, Robinson, Dan R., Sandhu, Shahneen, Fowler, Gemma, Ebbs, Berni, Flohr, Penny, Seed, George, Rodrigues, Daniel Nava, Boysen, Gunther, Bertan, Claudia, Atkin, Mark, Clarke, Matthew, Crespo, Mateus, Figueiredo, Ines, Riisnaes, Ruth, Sumanasuriya, Semini, Rescigno, Pasquale, Zafeiriou, Zafeiris, Sharp, Adam, Tunariu, Nina, Bianchini, Diletta, Gillman, Alexa, Lord, Christopher J., Hall, Emma, Chinnaiyan, Arul M., Carreira, Suzanne, de Bono, Johann S.·2017·Cancer Discovery

Abstract

Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity associating with homologous recombination DNA repair defects. We now report targeted and whole-exome sequencing of serial circulating cell-free DNA (cfDNA) samples collected during this trial. Decreases in cfDNA concentration independently associated with outcome in multivariable analyses (HR for overall survival at week 8: 0.19; 95% CI, 0.06–0.56; P = 0.003). All tumor tissue somatic DNA repair mutations were detectable in cfDNA; allele frequency of somatic mutations decreased selectively in responding patients (χ2 P < 0.001). At disease progression, following response to olaparib, multiple subclonal aberrations reverting germline and somatic DNA repair mutations (BRCA2, PALB2) back in frame emerged as mechanisms of resistance. These data support the role of liquid biopsies as a predictive, prognostic, response, and resistance biomarker in metastatic prostate cancer. Significance: We report prospectively planned, serial, cfDNA analyses from patients with metastatic prostate cancer treated on an investigator-initiated phase II trial of olaparib. These analyses provide predictive, prognostic, response, and resistance data with “second hit” mutations first detectable at disease progression, suggesting clonal evolution from treatment-selective pressure and platinum resistance. Cancer Discov; 7(9); 1006–17. ©2017 AACR. See related commentary by Domchek, p. 937. See related article by Kondrashova et al., p. 984. See related article by Quigley et al., p. 999. This article is highlighted in the In This Issue feature, p. 920

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-17-0261

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 421

Metadata

Authors
Goodall, J., Mateo, J., Yuan, W., Mossop, H., Porta, N., Miranda, S., Perez-Lopez, R., Dolling, D., Robinson, D. R., Sandhu, S., Fowler, G., Ebbs, B., Flohr, P., Seed, G., Rodrigues, D. N., Boysen, G., Bertan, C., Atkin, M., Clarke, M., Crespo, M., Figueiredo, I., Riisnaes, R., Sumanasuriya, S., Rescigno, P., Zafeiriou, Z., Sharp, A., Tunariu, N., Bianchini, D., Gillman, A., Lord, C. J., Hall, E., Chinnaiyan, A. M., Carreira, S., & de Bono, J. S.
Venue
Cancer Discovery
Published
2017-08-31
Volume
7
Issue
9
Pages
1006-1017
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2607665721
Cited by
421
References
36
FWCI
20.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. https://app.cochat.ai/papers/10.1158/2159-8290.cd-17-0261
The paper
Goodall, J., Mateo, J., Yuan, W., Mossop, H., Porta, N., Miranda, S., Perez-Lopez, R., Dolling, D., Robinson, D. R., Sandhu, S., Fowler, G., Ebbs, B., Flohr, P., Seed, G., Rodrigues, D. N., Boysen, G., Bertan, C., Atkin, M., Clarke, M., . . . de Bono, J. S. (2017). Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-17-0261

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.